L.E.K Consulting’s Dr Feras Mahdi highlights industry adoption of emerging healthcare technologies

He looks into how commercial strategies and technological and operational innovations are driving the healthcare industry today.

Advances in new medical technology and regulations, as well as rising patient demands, are mainly driving Asia’s healthcare industry today. From the adoption of AI-powered diagnostics to the scaling of innovative solutions, the region presents vast opportunities for growth.

At the forefront of navigating this transformation is L.E.K. Consulting Partner Dr Feras Mahdi, whose over two decades of experience span healthcare strategy, medtech commercialisation, and large-scale transformation projects across more than 25 countries. His unique blend of clinical expertise and business acumen offers a fresh perspective grounded in practical execution.

Speaking as a judge for the Healthcare Asia Awards 2026, Mahdi shares his insights on how the region’s healthcare industry is evolving, including strategic growth in medtech and the adoption of emerging technologies.

With over 20 years in the field, how have you seen the healthcare consulting landscape evolve, particularly in strategy and commercial growth for medical technology?

Healthcare consulting in Asia has moved closer to the operating core of providers and purchasers, and that shift has materially changed how medtech growth strategy is designed.

As purchasing mechanisms mature across the region — through more formal health technology assessment processes, bundled payments, DRG-like reimbursement logic, and increasingly sophisticated hospital procurement committees — commercial strategy can no longer rely on clinical differentiation alone. Budget holders now ask where economic value accrues: length of stay, complication avoidance, staffing time, downstream utilisation, consumables, and capital amortisation. In that environment, pricing architecture becomes strategic. Tiered pricing, risk-sharing models, and lifecycle costing discussions are increasingly relevant, particularly in upper-middle-income and developed Asian markets.

Parallel to this is the structural burden of chronic disease and ageing populations. OECD reporting continues to underscore the dominance of non-communicable diseases, including cardiovascular disease, across the Asia-Pacific. When demand is high and workforce capacity is constrained, technologies that increase procedural time, documentation burden, or administrative friction face resistance regardless of clinical merit. This has pushed medtech firms to think beyond device sales toward value-added services: training, workflow redesign support, data dashboards, predictive maintenance, digital integration, and outcome tracking.

Commercial engagement is therefore shifting from transactional sales to solution-based partnerships. Market access functions now sit closer to strategy. Economic fluency has become as important as clinical fluency. And success increasingly depends on whether a product fits within a system’s operational reality, not only whether it advances the standard of care.

Having led large-scale healthcare transformation projects, what approaches are most effective in implementing changes across Asia’s complex healthcare systems?

Transformation in Asia succeeds when operational redesign and disciplined communication advance together.

The starting point is almost always flow. Diagnostic turnaround time, theatre utilisation, discharge reliability, referral routing, and workforce allocation typically represent the binding constraints. OECD and WHO analyses across Asia-Pacific highlight uneven access and system bottlenecks that are financial and operational rather than purely clinical. Digitising inefficient pathways or expanding infrastructure without resolving discharge or referral friction rarely produces durable gains.

Governance must be explicit. Ownership of referral rules, standard work, pathway compliance, and data quality cannot remain diffuse. In many Asian systems, hierarchical structures coexist with fragmented operational authority. Transformation requires clarity on who can enforce change.

Communication has also become more sophisticated and more necessary. In the same way that industry has embraced omnichannel marketing, internal transformation requires layered communication strategies. Executives, clinical leaders, nursing staff, administrative teams, and regulators engage differently with change. Alignment depends on reinforcing the same operational logic across dashboards, clinical meetings, digital prompts, education sessions, and performance reviews. Without coherence across channels, transformation becomes episodic rather than structural.

Workforce constraints remain decisive. Global executive surveys consistently rank operational efficiency and staffing pressure amongst top concerns. In fast-growing Asian health systems, any intervention that increases net administrative load for clinicians will stall. The most resilient transformations are those that demonstrably remove steps, reduce duplication, and protect clinical time before layering additional tools.

Sequencing matters as well. Multi-site hospital groups and public systems require replicable designs and short-cycle pilots tied to measurable improvements to build credibility. Scaling follows.

How are public and private healthcare sectors in Asia adapting to AI-powered diagnostic tools and other emerging technologies?

AI adoption in Asia is increasingly defined by regulatory clarity, evidentiary expectations, and integration discipline.

Regulators in developed Asian markets, including Singapore’s Health Sciences Authority, have articulated lifecycle guidance for software medical devices, including AI-enabled systems. Expectations now cover validation, cybersecurity, version control, and post-deployment monitoring. This shifts AI from an exploratory technology into a governed clinical asset.

Evidence thresholds are rising accordingly. Health systems increasingly require performance metrics — diagnostic accuracy, turnaround reduction, documentation time saved, productivity impact — rather than narrative claims. Reporting on large provider groups illustrates how AI initiatives are framed around workload reduction and operational gains, while acknowledging integration hurdles such as fragmented EMR systems and uneven data maturity.

Workflow integration remains the practical determinant of success. AI that introduces additional review layers or duplicative documentation burdens clinicians. Early adoption, therefore, concentrates on high-yield, low-friction applications: radiology triage, documentation automation, appointment optimisation, remote monitoring, and structured triage support. These use cases offer measurable ROI and minimal disruption to core clinical processes.

At the same time, larger hospital networks are beginning to build internal analytics and AI capabilities. In-house teams allow adaptation to local data architecture and governance requirements, though they introduce talent and oversight challenges. Patient-facing technologies — both clinical and operational — are expanding in parallel. Digital appointment management, remote follow-up, and real-time visit tracking often deliver immediate improvements in adherence and no-show rates, making them attractive first investments.

How do cultural and socioeconomic factors in Asia influence the adoption of new medical technologies?

Adoption in Asia is shaped by geography, financing structure, and trust dynamics as much as by clinical capability.

Urban concentration remains a defining feature. Advanced technologies cluster in major metropolitan centres — Singapore, Seoul, Tokyo, Bangkok, and Shanghai — where capital, specialist workforce, and payer density converge. Secondary cities and rural regions often rely on referral linkages or telemedicine to access advanced services. Geographic concentration, therefore, influences early adoption patterns and reinforces centralised care models.

Out-of-pocket spending continues to represent a significant share of health expenditure in many Asian economies. This heightens sensitivity to total episode cost and predictability of payment. Technologies that reduce repeat visits, shorten hospital stays, or prevent complications may gain traction when framed through affordability and convenience rather than novelty.

Trust structures vary across markets. In some contexts, physician reputation drives adoption. In others, institutional brand, accreditation status, or insurer network alignment carries greater weight. Patient experience factors — waiting time, transparency, navigation ease — shape perceived value alongside clinical endpoints. These dimensions influence conversion rates and follow-up adherence, which in turn determine realised outcomes.

Socioeconomic stratification produces adoption gradients. Premium tertiary services may scale rapidly in affluent urban segments, while peripheral regions require simplified, digitally enabled pathways that compensate for workforce scarcity and infrastructure limitations. Technology design must reflect differences in digital literacy, connectivity reliability, and payment systems.

Looking ahead, which areas of Asia’s healthcare ecosystem hold the greatest potential for innovation and investment?

Innovation potential in Asia is best understood through structural necessity rather than export orientation.

Ageing populations, persistent non-communicable disease burden, workforce shortages, throughput bottlenecks, and geographic inequities define the region’s enduring pressures. Technologies and operating models that address these constraints are more likely to generate durable value than those orientated primarily toward global scalability.

Flow optimisation represents one such area. Diagnostic automation, theatre analytics, discharge coordination systems, and referral routing platforms create capacity without proportional staffing increases. Executive outlook surveys consistently highlight operational efficiency as a top priority, reinforcing demand for these solutions.

Workforce-relieving technologies are similarly positioned. AI-assisted documentation, triage support tools, and remote monitoring systems respond directly to clinician scarcity. Adoption accelerates when measurable reductions in workload accompany clinical benefit.

Geographically enabling technologies — telehealth integration, portable diagnostics, and coordinated referral networks — address the concentration of advanced care in major cities and extend capability to underserved regions. Their value lies in system connectivity rather than technological novelty alone.

Importantly, the highest-potential innovations are not necessarily those that mirror U.S. market structures. Many of Asia’s binding constraints are local: mixed public-private financing models, dense urban outpatient demand, regulatory variation, and uneven digital maturity. Solutions designed around these realities may achieve regional dominance even if they are not immediately global in scope.

Breakthrough technologies will emerge. Yet much of Asia’s durable innovation will be grounded in solving local system constraints with operationally credible models.

As a returning judge at the Healthcare Asia Awards 2026, what key qualities stand out to you when assessing nominated entries?

Across the 2025 and 2026 submissions, what stands out most is increasing operational maturity. More entries are presenting measurable change rather than descriptive ambition.

In 2026, there is a clear shift toward quantifying impact in ways that map directly to hospital operations. Several nominations move beyond narrative and present reductions in outpatient process steps through structured digital check-in, measurable declines in ICU documentation time, faster imaging turnaround, and lower no-show rates through redesigned appointment systems. These types of metrics reflect an understanding that innovation must translate into tangible improvements in flow and reliability.

Integration discipline is also more evident. Stronger digital submissions describe device-to-EHR connectivity, automated data transfer, and embedded reporting structures tied to time savings and workflow simplification. The emphasis is less on the presence of technology and more on how it is integrated into routine clinical practice.

Operational infrastructure initiatives are evolving similarly. Projects that quantify improvements in search time, delays, adverse events, and staff stress demonstrate attention to internal system reliability and patient safety through structured redesign.

Clinical pathway submissions continue to show disciplined measurement. Entries presenting mortality reduction, length-of-stay improvement, and compliance gains supported by defined coordination mechanisms illustrate outcome-oriented framing that is increasingly consistent across categories.

Sustainability initiatives are also becoming more operationally grounded. Submissions that measure reductions in resource use and link them to governance processes reflect a maturing approach to ESG within healthcare institutions.

Overall, the trajectory across the two years suggests that participating organisations are increasingly comfortable presenting performance data, operational mechanisms, and integration details. That evolution strengthens comparability and raises the overall standard of the awards.